Page 102 - 2019_01-Haematologica-web

M. Spagnuolo et al.
al. p53-dependent non-coding RNA net-
works in chronic lymphocytic leukemia.
Leukemia. 2015;29(10):2015-23.
26. Kuo WT, Yu SY, Li SC, et al. MicroRNA-324
in Human Cancer: miR-324-5p and miR- 324-3p Have Distinct Biological Functions in Human Cancer. Anticancer Res. 2016;36(10):5189-5196.
27. Tamaddon G, Geramizadeh B, Karimi MH, Mowla SJ, Abroun S. miR-4284 and miR- 4484 as Putative Biomarkers for Diffuse Large B-Cell Lymphoma. Iran J Med Sci. 2016;41(4):334-339.
28. Mogilyansky E, Rigoutsos I. The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increas- ingly important and numerous roles in health and disease. Cell Death Differ. 2013;20(12):1603-1614.
29. Scherr M, Elder A, Battmer K, et al. Differential expression of miR-17~92 identi- fies BCL2 as a therapeutic target in BCR- ABL-positive B-lineage acute lymphoblastic leukemia. Leukemia. 2014;28(3):554-565.
30. Ess KC, Whitaker TL, Cost GJ, Witte DP, Hutton JJ, Aronow BJ. A central role for a single c-Myb binding site in a thymic locus control region. Mol Cell Biol. 1995; 15(10):5707-5715.
31. Pelosi A, Careccia S, Lulli V, et al. miRNA let-7c promotes granulocytic differentiation in acute myeloid leukemia. Oncogene. 2013;32(31):3648-3654.
32. Surana R, Sikka S, Cai W, et al. Secreted friz- zled related proteins: Implications in can- cers. Biochim Biophys Acta. 2014;
1845(1):53-65.
33. Ventura A, Young AG, Winslow MM, et al.
Targeted deletion reveals essential and over- lapping functions of the miR-17 through 92 family of miRNA clusters. Cell. 2008;132(5):875-886.
40. Inomata M, Tagawa H, Guo YM, Kameoka Y, Takahashi N, Sawada K. MicroRNA-17- 92 down-regulates expression of distinct tar- gets in different B-cell lymphoma subtypes. Blood. 2009;113(2):396-402.
41. Leyns L, Bouwmeester T, Kim SH, Piccolo S, De Robertis EM. Frzb-1 is a secreted antag- onist of Wnt signaling expressed in the Spemann organizer. Cell. 1997; 88(6):747-
34. Mavrakis KJ, Wolfe AL, Oricchio E, et al. Genome-wide RNA-mediated interference
screen identifies miR-19 targets in Notch-
induced T-cell acute lymphoblastic 756.
leukaemia. Nat Cell Biol. 2010;12(4):372-
379.
35. Dews M, Homayouni A, Yu D, et al.
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet. 2006;38(9):1060-1065.
36. Mo W, Zhang J, Li X, et al. Identification of novel AR-targeted microRNAs mediating androgen signalling through critical path- ways to regulate cell viability in prostate cancer. PLoS One. 2013;8(2):e56592.
37. Psathas JN, Doonan PJ, Raman P, Freedman BD, Minn AJ, Thomas-Tikhonenko A. The Myc-miR-17-92 axis amplifies B-cell recep- tor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop. Blood. 2013;122(26):4220-4229.
38. Mu P, Han YC, Betel D, et al. Genetic dissec- tion of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev. 2009;23(24):2806-2811.
39. Xiao C, Srinivasan L, Calado DP, et al. Lymphoproliferative disease and autoimmu- nity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol. 2008;9(4):405-414.
42. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005; 434(7035): 843-850.
43. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005; 435(7043):828-833.
44. Olive V, Jiang I, He L. mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol. 2010; 42(8):1348-54.
45. Venturini L, Battmer K, Castoldi M, et al. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood. 2007;109(10):4399-4405.
46. Cogswell JP, Cogswell PC, Kuehl WM, et al. Mechanism of c-myc regulation by c-Myb in different cell lineages. Mol Cell Biol. 1993;13(5):2858-2869.
47. Ji M, Rao E, Ramachandrareddy H, et al. The miR-17-92 microRNA cluster is regulated by multiple mechanisms in B-cell malignancies. Am J Pathol. 2011; 179(4):1645-1656.
48. De Dominici M, Porazzi P, Soliera AR, et al. Targeting CDK6 and BCL2 exploits the "MYB addiction" of Ph+ acute lymphoblas- tic leukemia. Cancer Res. 2018;78(4):1097- 1109.
92
haematologica | 2019; 104(1)